Nevertheless, in a clinical perspective, our results suggest that the HLA-E-mediated protection of ΔTRACCARΔB2MHLAE is likely to occur in the vast majority of AML and ALL patients. This evidence concerns the gene HLA-E and acute myeloid leukemia.